Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The relationship between cholinergic dysfunction and cognitive and functional impairment in patients with vascular dementia (VaD) and Alzheimer's disease (AD) with cerebrovascular disease (CVD) suggests a potential role for cholinomimetic therapy. Initial studies of galantamine demonstrated cognitive, behavioral, and functional benefits in these populations. 326 patients with VaD or AD with CVD who completed an initial 12‐month trial were treated with galantamine 24 mg/day in a 24‐month, open‐label extension. This interim analysis was performed at month 12 of the open‐label extension (248 completed the trial). Galantamine (up to 24 months total) was well tolerated in both groups. The most frequently reported adverse events, characteristic of older dementia patients, included depression, agitation, and insomnia. Gastrointestinal adverse events were less common than initially, indicating declining incidence with long‐term therapy. Patients taking galantamine for the entire study demonstrated the least cognitive decline on AD Assessment Scale‐cog/11: 2.7 points vs. 3.1 points in those given placebo initially (P < 0.001 and P = 0.003, respectively). The long‐term benefits of galantamine were evident in both groups; cognitive baseline levels were maintained for approximaely 21 months in VaD patients and for 12 months in patients with AD with CVD. Long‐term (up to 24 months) galantamine therapy in patients with VaD and AD with CVD is well tolerated and associated with prolonged maintenance of cognitive function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Self-citationOrgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539 · cited 2×
“There was a higher percentage of men (55.5% overall) in this study because of the higher prevalence of vascular risk factors in men; this percentage is consistent with other studies conducted in VaD patients (Orgogozo et al., 2002; Pratt, 2002; Wilcock et al., 2002).”
ResultInfluential(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Wilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381 · cited 2×
“There was a higher percentage of men (55.5% overall) in this study because of the higher prevalence of vascular risk factors in men; this percentage is consistent with other studies conducted in VaD patients (Orgogozo et al., 2002; Pratt, 2002; Wilcock et al., 2002).”
ResultInfluentialMaelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · cited 2×
“Galantamine, the most recent addition to the AChEI class, is the only agent available with a dual mechanism of action that includes enzyme inhibition and allosteric modulation of nicotinic acetylcholine receptors (Samochocki et al., 2000; Maelicke et al., 2001).”
Background
Cited by
Leys, D., Hénon, H., Mackowiak-Cordoliani, M.-A., & Pasquier, F. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70221-0 · Cited by 609
Galantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 266
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Treatment of vascular dementia—evidence from clinical trials with cholinesterase inhibitors
Erkinjuntti, T., Román, G., & Gauthier, S. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.018 · Cited by 82
Self-citation
Metadata
- Authors
- Kurz, A. F., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. R. V.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2003-10-22
- Volume
- 10
- Issue
- 6
- Pages
- 633-640
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2065735162
- Cited by
- 54
- References
- 6
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. https://app.cochat.ai/papers/10.1046/j.1468-1331.2003.00677.x
- The paper
- Kurz, A. F., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. R. V. (2003). Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. European Journal of Neurology. https://doi.org/10.1046/j.1468-1331.2003.00677.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.